Publication

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt to detect fibrosis stages in patients with metabolic […]

Non- Invasive Initiation & Monitoring of Resmetirom (RT) Therapy Using LIVERFASt, FIB-4, and VCTE in MASH Patients

The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy

LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients

In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4

The Utility of Non-Invasive Tests (NITs) – LIVERFASt, FIB4 and VCTE (Fibroscan) in MASH Patients

This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.

Association between Psoriasis Severity & Steatosis Measured by AI-based Algorithm (LIVERFAStTM)

This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe

Combination of LIVERSTAT (LST) and Fibroscan (LSM) Outperforms FIB-4 and LSM for MASLD Advanced Fibrosis

Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those

Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) in patients with type 2 diabetes (T2D)

Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in

LIVERFASt: Non-Invasive Liver Assessment for Chronic Hepatitis B & Diabetes

This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and

Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy

MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis

Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure

Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents